Agreement - February 22, 2017
AstraZeneca in agreement with TerSera Therapeutics
AstraZeneca has entered into an agreement with TerSera Therapeutics (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders. It was first approved in the US and Canada in 1989. […]